These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 22325915)

  • 1. Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro.
    Shah M; Gallipoli P; Lyons J; Holyoake T; Jørgensen H
    Blood Cells Mol Dis; 2012 Mar; 48(3):199-201. PubMed ID: 22325915
    [No Abstract]   [Full Text] [Related]  

  • 2. Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells.
    Tanaka R; Squires MS; Kimura S; Yokota A; Nagao R; Yamauchi T; Takeuchi M; Yao H; Reule M; Smyth T; Lyons JF; Thompson NT; Ashihara E; Ottmann OG; Maekawa T
    Blood; 2010 Sep; 116(12):2089-95. PubMed ID: 20548094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone H3 covalent modifications driving response of BCR-ABL1+ cells sensitive and resistant to imatinib to Aurora kinase inhibitor MK-0457.
    Mancini M; Aluigi M; Leo E; Marcozzi C; Castagnetti F; Barbieri E; Santucci MA
    Br J Haematol; 2012 Jan; 156(2):265-8. PubMed ID: 22103975
    [No Abstract]   [Full Text] [Related]  

  • 4. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
    Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AT9283 exhibits antiproliferative effect on tyrosine kinase inhibitor‑sensitive and ‑resistant chronic myeloid leukemia cells by inhibition of Aurora A and Aurora B.
    Takeda T; Tsubaki M; Genno S; Nemoto C; Onishi Y; Yamamoto Y; Imano M; Satou T; Nishida S
    Oncol Rep; 2020 Nov; 44(5):2211-2218. PubMed ID: 33000229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.
    Gontarewicz A; Balabanov S; Keller G; Colombo R; Graziano A; Pesenti E; Benten D; Bokemeyer C; Fiedler W; Moll J; Brümmendorf TH
    Blood; 2008 Apr; 111(8):4355-64. PubMed ID: 18268096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro.
    Balabanov S; Gontarewicz A; Keller G; Raddrizzani L; Braig M; Bosotti R; Moll J; Jost E; Barett C; Rohe I; Bokemeyer C; Holyoake TL; Brümmendorf TH
    PLoS One; 2011 Apr; 6(4):e19164. PubMed ID: 21541334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
    Chu S; Holtz M; Gupta M; Bhatia R
    Blood; 2004 Apr; 103(8):3167-74. PubMed ID: 15070699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance.
    Tseng PH; Lin HP; Zhu J; Chen KF; Hade EM; Young DC; Byrd JC; Grever M; Johnson K; Druker BJ; Chen CS
    Blood; 2005 May; 105(10):4021-7. PubMed ID: 15665113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas.
    Qi W; Liu X; Cooke LS; Persky DO; Miller TP; Squires M; Mahadevan D
    Int J Cancer; 2012 Jun; 130(12):2997-3005. PubMed ID: 21796626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.
    Gontarewicz A; Balabanov S; Keller G; Panse J; Schafhausen P; Bokemeyer C; Fiedler W; Moll J; Brümmendorf TH
    Leuk Res; 2008 Dec; 32(12):1857-65. PubMed ID: 18514829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.
    Dasmahapatra G; Patel H; Nguyen T; Attkisson E; Grant S
    Clin Cancer Res; 2013 Jan; 19(2):404-14. PubMed ID: 23204129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards a cure for chronic myeloid leukemia: are we there yet?
    Cortes J
    Semin Hematol; 2010 Oct; 47(4):299-301. PubMed ID: 20875545
    [No Abstract]   [Full Text] [Related]  

  • 14. Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283.
    Curry J; Angove H; Fazal L; Lyons J; Reule M; Thompson N; Wallis N
    Cell Cycle; 2009 Jun; 8(12):1921-9. PubMed ID: 19440047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Bcr/Abl kinase antagonist for chronic myelogenous leukemia: a promising path for progress emerges.
    Sausville EA
    J Natl Cancer Inst; 1999 Jan; 91(2):102-3. PubMed ID: 9923844
    [No Abstract]   [Full Text] [Related]  

  • 16. T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study.
    Pricl S; Fermeglia M; Ferrone M; Tamborini E
    Mol Cancer Ther; 2005 Aug; 4(8):1167-74. PubMed ID: 16093432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells.
    Parmar S; Smith J; Sassano A; Uddin S; Katsoulidis E; Majchrzak B; Kambhampati S; Eklund EA; Tallman MS; Fish EN; Platanias LC
    Blood; 2005 Oct; 106(7):2436-43. PubMed ID: 15790787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcription suppression of SARI (suppressor of AP-1, regulated by IFN) by BCR-ABL in human leukemia cells.
    Huang Q; Yang Y; Li X; Huang S
    Tumour Biol; 2011 Dec; 32(6):1191-7. PubMed ID: 21892628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.
    Yokota A; Kimura S; Masuda S; Ashihara E; Kuroda J; Sato K; Kamitsuji Y; Kawata E; Deguchi Y; Urasaki Y; Terui Y; Ruthardt M; Ueda T; Hatake K; Inui K; Maekawa T
    Blood; 2007 Jan; 109(1):306-14. PubMed ID: 16954504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.
    Cassuto O; Dufies M; Jacquel A; Robert G; Ginet C; Dubois A; Hamouda A; Puissant A; Luciano F; Karsenti JM; Legros L; Cassuto JP; Lenain P; Auberger P
    Oncotarget; 2012 Dec; 3(12):1557-65. PubMed ID: 23238683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.